Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,113.1
42.0 (1.37%)

 

  • STI Straits Times Index
    3,113.1
    42.0 (1.37%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,623.4
    11.6 (0.72%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,994.5
    453.7 (1.59%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,412.6
    -8.8 (-0.26%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,800.8
    57.6 (0.20%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,255.3
    6.8 (0.11%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 816.5M
  • Value: 894.8M
  • Rise: 151
  • Fall: 114
  • Unch: 510

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Oceanus^0.037-0.006
Sembcorp Marine0.161+0.001
CWX Global0.006+0.001
Jiutian Chemical0.080-
Shen Yao0.004-
FJ Benjamin0.045+0.001
Enviro-Hub0.075+0.002
3Cnergy0.020+0.002
ComfortDelGro1.700+0.060
YZJ Shipbldg SGD1.100-0.010

World Indices

World Indices
Name Last Change
Nasdaq 12,609.2 -311.0
HSI 28,913.4 +372.6
HSCEI 11,083.2 +68.4
Jakarta 6,253.4 +4.9
Nikkei 225 28,800.8 +57.6
SSE Comp 3,412.5 -8.9
Shanghai A 3,576.9 -9.4
Shanghai B 242.3 +1.1
KOSPI 2,972.3 -23.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

KINTOR PHARMA-B KINTOR PHARMA-B
Quotes 15 Minutes Delayed. Updated at 09 Mar 2021 11:29
Last (HKD): 18.500 Change: +1.000 High: 18.520 Remarks: -
Change (%): +5.71 Low: 17.520
Open 17.520 Yesterday's Close 17.500
Buy Price 18.180 Sell Price 18.440
Buy Volume ('000) 3.5 Sell Volume ('000) 8
Cumulative Volume ('000) 559.5 Cumulative Value 10,226,110
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a -0.71853 Trailing EPS (HKD) e -0.99428 NAV (HKD) b 5.3755
PE a - Trailing PE f - Price / NAV b 3.4415
Dividend (HKD) d - Cash In Hand (HKD) g 5.3497 Issued & Paid-up Shares c 367,028,641
Dividend Yield (%) d - Price / Cash In Hand g 3.458 Treasury Shares h 2,361,359
Beta - 75 Daysi 0.821 R-Squared - 75 Days(%)i 1.40 Market Cap (M) 6,790.030
Beta - 500 Daysi 0.457 R-Squared - 500 Days (%)i 1.00 Enterprise Value (M) 5,058.995
Piotroski F Score 2 Exchange Code 9939 Par Value ( USD ) 0.00010
52 Weeks Volatility (%) n.a. 6-Month VWAP 12.938 Free Float (%) 92.6
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 24 Aug 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 24 Aug 2020.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference KINTOR PHARMA-B HKEx 6,790.030 - - 3.4415 -
Industry Biotechnology HKEx 40,166.412 - - 7.1464 0.116
Local Peer WUXI BIO HKEx 363,967.468 316.609 252.771 24.3652 -
Local Peer BEIGENE HKEx 209,434.720 - - 6.9808 -
Local Peer SINO BIOPHARM HKEx 150,886.941 49.160 58.962 4.1865 0.665
Local Peer ZAI LAB-SB HKEx 87,011.922 - - 9.5966 -
Local Peer JOINN HKEx 34,605.658 162.473 141.803 31.3320 0.179
Local Peer GENSCRIPT BIO HKEx 26,195.591 - - 3.5828 -
Local Peer 3SBIO HKEx 18,288.484 16.564 12.180 1.5635 -
Local Peer VIVA BIOTECH HKEx 13,145.955 43.605 - 6.3191 0.238
Local Peer JACOBIO-B HKEx 11,618.218 - - -8.2638 -
Local Peer JW THERAP-B HKEx 11,687.407 - - -11.5320 -
Local Peer ALPHAMAB-B HKEx 11,181.870 - - 3.9490 -
Local Peer HAOHAI BIOTEC HKEx 9,631.779 37.255 37.255 1.4795 -
Other Local Peers FRONTAGE (HKEx), JHBP-B (HKEx), ASCENTAGE-B (HKEx), SINOMAB BIO-B (HKEx), LEE'S PHARM (HKEx), ESSEX BIO-TECH (HKEx), ASCLETIS-B (HKEx), UNI-BIO GROUP (HKEx), REGENT PACIFIC (HKEx), HAO WEN HLDGS (HKEx)
Global Peer AMGEN INC NASDAQ 131,575.310 18.113 18.113 13.9840 2.813
Global Peer CSL LTD ASX 111,959.520 35.698 29.418 10.5949 1.193
Global Peer GILEAD SCIENCES INC NASDAQ 81,364.202 661.524 661.498 4.4701 4.192
Global Peer ILLUMINA INC NASDAQ 55,970.158 85.320 85.320 11.9238 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 55,522.257 20.475 20.475 6.3915 -
Global Peer MODERNA INC NASDAQ 49,359.602 - - 19.2708 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 49,622.457 14.125 14.125 4.5008 -
Global Peer BIOGEN INC NASDAQ 41,132.243 10.282 10.282 3.8440 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 32,990.391 54.674 54.674 2.8315 -
Global Peer BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS NASDAQ 26,957.682 - - 6.9672 -
Other Global Peers SEAGEN INC (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), INCYTE CORPORATION (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), BIO-TECHNE CORP (NASDAQ), NOVAVAX INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), Lonza (SGX), PTC THERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), INSMED INC (NASDAQ), ARVINAS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), VERACYTE INC (NASDAQ), ALKERMES PLC (NASDAQ), NANTKWEST INC (NASDAQ), VIELA BIO INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), SEER INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), LIGAND PHARMACEUTICAL INC (NASDAQ), NUVATION BIO INC (NYSE), KYMERA THERAPEUTICS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), ALLOVIR INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), STOKE THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), PRECIGEN INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), REGENXBIO INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), OCUGEN INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), BIOATLA INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), NKARTA INC (NASDAQ), CYTOKINETICS INC (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALECTOR INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), IMMUNOVANT INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), ITEOS THERAPEUTICS INC (NASDAQ), VAXCYTE INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), OMEROS CORP (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), CORTEXYME INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), MESOBLAST LTD (ASX), BIOXCEL THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PASSAGE BIO INC (NASDAQ), PERSONALIS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), INHIBRX INC (NASDAQ), EPIZYME INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MERUS B V (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), SOLID BIOSCIENCES INC (NASDAQ), CHIMERIX INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), KADMON HLDGS INC (NASDAQ), HUMANIGEN INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), VAXART INC (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), ATHIRA PHARMA INC (NASDAQ), COMPUGEN (NASDAQ), ATRECA INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), IMMATICS N V (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), AFFIMED N V (NASDAQ), AGENUS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ARDELYX INC (NASDAQ), AKOUOS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), GERON CORP (NASDAQ), XBIOTECH INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), IVERIC BIO INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), ALTIMMUNE INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AVROBIO INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), DPHARMA (Bursa), SINOVAC BIOTECH LTD (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), ADICET BIO INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), XOMA CORP (NASDAQ), CUE BIOPHARMA INC (NASDAQ), OPTHEA LIMITED (ASX), PORTAGE BIOTECH INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), SESEN BIO INC (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), VERASTEM INC (NASDAQ), ATHERSYS INC (NASDAQ), ONCORUS INC (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), IMUGENE LIMITED (ASX), CO DIAGNOSTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), NANOVIRICIDES INC (NYSE American), APTOSE BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), IMMUNOME INC (NASDAQ), NEXTCURE INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), GREENWICH LIFESCIENCES INC (NASDAQ), KAMADA LTD (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), MEDICINOVA INC (NASDAQ), CABALETTA BIO INC (NASDAQ), ANTEOTECH LIMITED (ASX), LARIMAR THERAPEUTICS INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), T2 BIOSYSTEMS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), METACRINE INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), IMV INC (NASDAQ), INMUNE BIO INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), BIOVIE INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), BIONOMICS LTD (ASX), NEXT SCIENCE LTD (ASX), SEELOS THERAPEUTICS INC (NASDAQ), CEL-SCI CORP (NYSE American), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), CHIASMA INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ORGENESIS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), EVOGENE LTD (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), BIOMX INC (NYSE American), DIAMEDICA THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD (ASX), AZIYO BIOLOGICS INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), CONTRAFECT CORP (NASDAQ), ENZO BIOCHEM INC (NYSE), IBIO INC (NYSE American), LEAP THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), LONGEVERON INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), ARAVIVE INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), ONCOLYTICS BIOTECH INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), SYNLOGIC INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), INFLARX N V (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), RECRO PHARMA INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), DIFFUSION PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), SAVARA INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), AIKIDO PHARMA INC (NASDAQ), COHBAR INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), LEAF RESOURCES LTD (ASX), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ADVAXIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CHIMERIC THERAPEUTICS LTD (ASX), CYNATA THERAPEUTICS LTD (ASX), MONOPAR THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), AZURRX BIOPHARMA INC (NASDAQ), VACCINEX INC (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), GENETIC TECHNOLOGIES (ASX), WINDTREE THERAPEUTICS INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BIOCARDIA INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), MEMPHASYS LTD (ASX), OPIANT PHARMACEUTICALS INC (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACORDA THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), SOLIGENIX INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), CYCLACEL PHARMACEUTICALS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ORAGENICS INC (NYSE American), ARCA BIOPHARMA INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), PRECIPIO INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), BIOTRON (ASX), CYCLO THERAPEUTICS INC (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), PHIO PHARMACEUTICALS CORP (NASDAQ), PATRYS LIMITED (ASX), Suntar Eco-City (SGX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ADALTA LTD (ASX), HISTOGEN INC (NASDAQ), INMED PHARMACEUTICALS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), CONSTELLATION TECHNOLOGIES LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), PLUS THERAPEUTICS INC (NASDAQ), GEOVAX LABS INC (NASDAQ), REGENEUS LTD (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), SENECA BIOPHARMA INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), SENESTECH INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), CRYOSITE (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.600
+3.35 %
10 Days -+1.440
+8.44 %
20 Days -+4.800
+35.04 %
Medium Term Return 3 Months -+10.660
+135.97 %
6 Months -+5.620
+43.63 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 7.200 - 22.950 Change From 1 Year Low +11.300 % Change From 1 Year Low (%) +156.94
Change From 1 Year High -4.450 % Change From 1 Year High (%) -19.39
2 Years Range 7.200 - 22.950 Change From 2 Years Low +11.300 % Change From 2 Years Low (%) +156.94
Change From 2 Years High -4.450 % Change From 2 Years High (%) -19.39
5 Years Range 7.200 - 22.950 Change From 5 Years Low +11.300 % Change From 5 Years Low (%) +156.94
Change From 5 Years High -4.450 % Change From 5 Years High (%) -19.39
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which focuses on the proprietary research and development of innovative medicine products for cancers and other Androgen receptor-related diseases. Its drug candidate, Proxalutamide, is undergoing phase III clinical trials in China and phase II clinical trials in the United States for metastatic castration resistant prostate cancer (mCRPC) as well as clinical trials for breast cancer. The firms product pipe line includes small molecule innovative drugs, bioinnovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as AR-Degrader, c-Myc inhibitors and IDO inhibitors that are undergoing preclinical research. The company was founded by Youzhi Tong and Chuangxing Guo on March 24, 2009 and is headquartered in Suzhou, China.

Historical Price Data

Date Open High Low Close Volume VWAP
08 Mar 2021 18.360 19.240 17.320 17.500 877,500 18.6976
05 Mar 2021 17.400 18.880 16.500 18.100 1,511,500 18.1600
04 Mar 2021 18.200 18.560 17.100 17.400 1,138,000 17.9173
03 Mar 2021 18.500 18.500 17.880 18.200 373,500 18.1562
02 Mar 2021 18.320 19.240 17.920 18.020 1,481,000 18.5785
01 Mar 2021 17.320 18.240 17.280 17.900 849,000 17.9595
26 Feb 2021 16.880 17.520 16.520 16.880 629,000 17.1162
25 Feb 2021 16.720 18.500 16.720 17.680 1,186,000 17.9728
24 Feb 2021 16.900 17.700 16.300 16.700 735,000 16.9696
23 Feb 2021 17.060 17.400 16.500 16.660 878,000 16.8397
22 Feb 2021 17.520 18.200 16.880 17.060 640,000 17.3208
19 Feb 2021 17.500 18.000 16.980 17.900 399,400 17.6362
18 Feb 2021 17.760 18.080 16.400 18.000 1,598,000 17.2812
17 Feb 2021 18.940 18.940 17.600 17.760 1,741,000 18.0590
16 Feb 2021 16.440 18.820 16.420 18.400 3,971,000 18.2069
11 Feb 2021 14.500 16.320 14.500 16.100 1,835,000 15.3925
10 Feb 2021 14.200 14.300 13.780 14.220 560,500 14.0854
09 Feb 2021 13.800 14.280 13.540 14.220 600,500 14.0197
08 Feb 2021 13.060 13.720 13.020 13.700 480,000 13.5147
05 Feb 2021 13.540 13.800 12.880 12.900 581,500 13.0452
04 Feb 2021 13.500 13.880 13.200 13.460 301,500 13.4753
03 Feb 2021 13.700 13.700 13.200 13.300 559,500 13.3233
Summary
Current 2 Weeks
(23 Feb 2021 to 08 Mar 2021)
17.060 19.240 16.300 17.500 9,658,500 -
Previous 2 Weeks
(05 Feb 2021 to 22 Feb 2021)
13.540 19.240 12.880 17.060 12,406,900 -
4 Weeks from
(08 Jan 2021 to 04 Feb 2021)
10.060 19.240 9.960 13.460 18,831,300 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.